|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Research Desk Line-up: Biogen Post Earnings Coverage LONDON, UK / ACCESSWIRE / July 27, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Nivalis Therapeutics, ...
Alpine Immune Sciences, Inc. , a leading company focused on the development of proprietary, protein-based immunotherapies to modulate the immune system, today announced the closing of its previously disclosed merger with Nivalis Therapeutics , effective July 24, 2017.
On a per-share basis, the Boulder, Colorado-based company said it had a loss of 24 cents. Losses, adjusted for restructuring costs, were 18 cents per share. The results exceeded Wall Street expectations. ...
ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.
Nivalis Therapeutics, Inc. announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held July 19, 2017, its stockholders approved all of the merger-related proposals, including: the Agreement and Plan of Merger and Reorganization, dated as of April 18, 2017, by and among Nivalis, Nautilus Merger Sub, Inc.
Nivalis Therapeutics, Inc. announced today that it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Alpine Immune Sciences, Inc.
Shire plc (SHPG) reported first-quarter 2017 earnings of $3.63 per American Depositary Share (ADS), beating the Zacks Consensus Estimate of $3.22 and up 13.8% from the year-ago quarter figure of $3.19.
AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of 99 cents per share in the first quarter of 2017 compared with earnings of 68 cents in the year-ago quarter
The Boulder, Colorado-based company said it had a loss of 57 cents per share. Losses, adjusted for restructuring costs, were 35 cents per share. In the final minutes of trading on Monday, the company's ...
Nivalis Therapeutics, Inc. , a pharmaceutical company historically focused on developing innovative solutions for people with cystic fibrosis , today reported financial results and recent business highlights for the first quarter 2017.
Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%.
The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.
Alpine Immune Sciences, a cancer immunotherapy company founded by former Dendreon CEO Mitch Gold, is listing publicly through a merger with Nivalis Therapeutics.
Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc., a privately-held biotechnology company developing novel therapies using its next-generation immune system modulation platform, today jointly announced they have entered into a definitive merger agreement under which Alpine will merge with a wholly-owned subsidiary of Nivalis in an all-stock transaction.
Success in late stage studies evaluating VX-661 + Kalydeco combo paves the way for approval application submission by Q3 2017
NEW YORK, NY / ACCESSWIRE / March 15, 2017 / Biotech stocks are among the most volatile sectors on the market as much of their stock price is directly connected to the success or failure of their niche ...
This week was a good one for a few biotechs, but not so great for others. Two in particular have just put out news relating to trials for their lead investigative assets, and both have taken a hit on the back of the release. Here’s a look at the companies in question, what happened, and […]
On a per-share basis, the Boulder, Colorado-based company said it had a loss of 50 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.